1. Patients must be currently receiving treatment with Tenalisib on a previously approved protocol.

2. Patients must have had at least one efficacy evaluation in previous study and should have achieved either SD, PR or CR.

3. Patients must have completed at least 6 cycles of Tenalisib in previous study

4. Ability to swallow and retain oral medication.

5. Female patients of child-bearing potential must consent to use two medically acceptable methods of contraception.

6. Male patients must be willing to use adequate contraceptive measures

7. Willingness and ability to comply with trial and follow-up procedures.

8. Willingness to provide new written informed consent.

Compassionate Use Study of Tenalisib (RP6530)